Mutation tracking in circulating tumour DNA (ctDNA) detects minimal residual disease (MRD) in patients with localized colorectal cancer (CRC) and identifies those at high risk of recurrence regardless of stage, lack of CDX2 expression and CMS subtype

Llavero, N. Tarazona; Gimeno-Valiente, Francisco; Gambardella, Valentina; Huerta, Marisol; Keränen, S. Roselló; Bruixola, Gema; Fontana, Elisa; Martínez-Ciarpaglini, Carolina; Zúñiga, S.; Rentero, P.; Fleitas, Tania; Papaccio, Federica; Moro, D.; Plá, Vicent Fonollosa; Nyamundanda, Gift; Castillo, Josefa; Sadanadam, A.; Espí, Alejandro; Roda, Desamparados

doi:10.1093/annonc/mdz246

Cited by 13 publications

(10 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These negative data are consistent with the findings by Hansen et al, who had reported a negative prognostic impact of CDX2 on DFS in two independent cohorts of patients with stage II CC [31]. The recent prospective single-center cohort analysis of patients with stage I-III CC by Llavero et al also confirmed the negative prognostic value of the loss of CDX2 protein expression (P = 0.004) [32]. The association of CDX2 expression with survival was also investigated by Tomasello et al in their meta-analysis of 16 studies including 6.291 patients from all stages (85% stage II-III CC) [33].…”

Section: Cdx2 Expressionsupporting

confidence: 89%

See 1 more Smart Citation

A comprehensive overview of promising biomarkers in stage II colorectal cancer

Parent

Cohen

Rassy

et al. 2020

Cancer Treatment Reviews

View full text Add to dashboard Cite

Section: Cdx2 Expressionsupporting

confidence: 89%

“…Several prospective studies have shown that ctDNA is a prognostic factor in resected stage II and III CC [32,79,80]. The assessment of a post-operative ctDNA level, either by mutation tracking or by methylated markers searching, can represent an evaluation of minimal residual disease [32,79,81].…”

Section: Circulating Tumor Dna (Ctdna)mentioning

confidence: 99%

A comprehensive overview of promising biomarkers in stage II colorectal cancer

Parent

Cohen

Rassy

et al. 2020

Cancer Treatment Reviews

View full text Add to dashboard Cite

“…The combination was well tolerated, and among 22 evaluable patients, the ORR was 55%, with the median PFS of 6.2 months and the median OS of 17.3 months. The trial is currently enrolling in the randomized part of the study, testing tucatinib plus trastuzumab versus tucatinib monotherapy [ 65 ].…”

Section: Recent Developments and Ongoing Clinical Trialsmentioning

confidence: 99%

Tackling Refractory Metastatic Colorectal Cancer: Future Perspectives

Personeni

Smiroldo

Giunta

et al. 2021

Cancers

View full text Add to dashboard Cite

Substantial improvements have characterized the systemic treatment of metastatic colorectal cancer (mCRC) over the past 20 years. Besides strong evidence that supports the use of RAS and BRAF status as prognostic and predictive indicators of disease and response, novel technologies have made possible the incorporation of emerging biomarkers for the management of mCRC. On one hand, the discovery of point mutations, amplifications, fusions, and gene expression profiles highlights the genomic and dynamic complexity of CRC. On the other, such discoveries are leading to newer biomarker-driven strategies that add to existing anti-epidermal growth factor receptor (EGFR) and anti-angiogenic approaches. In addition, the availability of a wide molecular profiling has relevant implications for patient prognosis and treatment benefits. Here, we will review the molecular underpinnings and clinical data supporting novel targeted treatments under development for refractory mCRC harboring BRAF mutations, KRAS G12C mutations, HER2 amplification, and less common molecular alterations, such as the re-arrangements of NTRK, ALK, and ROS1. Additionally, we will discuss novel strategies driving the rechallenge of EGFR antibodies and the incorporation of newer anti-angiogenic agents in the therapeutic armamentarium.

show abstract

“…More recently, a triple combination of targeted agents against the MAPK pathway (panitumumab plus encorafenib plus binimetinib) proved its activity against BRAF mutant mCRC [5]. Moreover, ERBB2 amplification has been identified as a druggable target with promising results from several phase II trials [6][7][8], and HER2-targeted combinations included in international guidelines for mCRC [9]. CRC carcinogenesis is due to a complex and well-characterized cascade of molecular events [10].…”

Section: Introductionmentioning

confidence: 99%

The DNA damage response pathway as a land of therapeutic opportunities for colorectal cancer

et al. 2020

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

Mutation tracking in circulating tumour DNA (ctDNA) detects minimal residual disease (MRD) in patients with localized colorectal cancer (CRC) and identifies those at high risk of recurrence regardless of stage, lack of CDX2 expression and CMS subtype

Cited by 13 publications

References 0 publications

A comprehensive overview of promising biomarkers in stage II colorectal cancer

A comprehensive overview of promising biomarkers in stage II colorectal cancer

Tackling Refractory Metastatic Colorectal Cancer: Future Perspectives

The DNA damage response pathway as a land of therapeutic opportunities for colorectal cancer

Contact Info

Product

Resources

About